SSPOP Gene Mutations Linked to Pediatric Epilepsy and Developmental Delay

Disorders affecting the nervous system are now the leading global cause of disability, accounting for 443 million disability-adjusted life-years (a metric representing the total years of healthy life lost to disease) in 2021 [1]. Although next-generation sequencing provides significantly higher diagnostic yields than traditional chromosomal microarrays, approximately 65% to 70% of patients with neurodevelopmental disorders still lack a definitive molecular diagnosis [2]. This diagnostic gap is particularly critical in early-onset or drug-resistant epilepsy, where identifying specific drivers, such as variants in the NEXMIF gene associated with Jeavons syndrome (a generalized epilepsy characterized by eyelid myoclonia and photosensitivity), is essential for tailoring clinical management [2, 3]. Recent genomic analyses of over 29,000 individuals suggest that much of this phenotypic variety stems from the genetic architecture affecting synaptic processes in both excitatory and inhibitory neurons [4, 5]. A recent study further expands this landscape by identifying a functional role for SSPOP, a presumed pseudogene (a DNA sequence that resembles a gene but was previously thought to be biologically inert), in the pathogenesis of epilepsy and developmental delay [6].